ETF Explainer: ARKG

The genomics fund outperformed the broad health care space.

Reviewed by: Heather Bell
Edited by: Heather Bell

Each month, we look at an ETF selected by based on its performance and importance to investors. This month, we consider the performance of the $9.1 billion ARK Genomic Revolution ETF (ARKG), which targets companies engaged in disruptive innovation. All the companies mentioned below are holdings in ARKG, unless otherwise noted (*).



For a larger view, please click on the image above.


APR 17 The FDA begins a priority review of Regeneron’s Ebola virus treatment, setting it up to become the first approved treatment for the disease and boosting the company’s share price.

JUN 11 Pacific Biosciences sees its share price fall sharply after it files for a mixed-shelf offering of new shares and its CEO of eight years announces his retirement.

AUG 7 Teladoc Health’s share price plunges after it announces it will absorb Livongo for $18.5 billion, with investors fearing a potentially inflated valuation.

OCT 15 Vertex Pharmaceuticals’ stock drops on news that it had to discontinue trials in one of its drugs under development due to patients exhibiting undesirable side effects.

DEC 7 Fate Therapeutics sees its stock price surge on good news regarding two of its immunotherapy treatments for different types of cancer.

JAN 19 Twist Bioscience announces licensing deals with Serotiny and Applied StemCell with the purpose of developing new antibody therapies.

Source: Bloomberg; data for 3/31/2020-3/31/2021

Heather Bell is a former managing editor of She has also held editorial positions at Dow Jones Indexes and Lehman Brothers. Bell is a graduate of Dartmouth college and resides in the Denver area with her two dogs.